Viatris closes Pacira buy, taking its pain bet live as mid-cap deal flow builds
With the $36.50-a-share tender complete and $90-100 million of revenue guided by year-end, Viatris has a new non-opioid pain franchise, and a crowded week of deals puts it in context.
What happened
Viatris has completed its cash acquisition of Pacira BioSciences at $36.50 a share, closing after a tender offer in which about 66.46% of Pacira's shares were tendered. Viatris describes Pacira as a non-opioid pain company and expects the acquisition to bring $90-100 million of revenue by year-end.
The material available to us does not give the headline transaction value, the product-level revenue split or any synergy targets, so we do not estimate them here. The revenue expectation is the one hard commercial marker. It is a near-term contribution figure, which suggests Viatris wants the market to see an immediate top-line effect rather than a long-dated promise.
The 66.46% tender figure is the other detail worth noting. It shows that most, but not all, holders tendered. The story does not spell out how the remaining shares will be handled, so readers should check the closing documents for the mechanics.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Sources
- Viatris completes $36.50-a-share cash acquisition of Pacira BioSciences after tender offer Viatris Inc · 17 Nov 2026
- UL Solutions to acquire supply chain software firm Worldly in roughly $350M deal UL Solutions Inc. · 17 Nov 2026
- Gedeon Richter to acquire Mayne Pharma in AUD 604 million cash deal Gedeon Richter · 16 Nov 2026
- Aytu BioPharma to be acquired by Rosemont for about $56M as EXXUA sales grow Aytu Biopharma, Inc · 16 Nov 2026
- Merck KGaA to acquire Rapid Micro Biosystems in $0.75-per-share cash tender offer Rapid Micro Biosystems, Inc. · 16 Nov 2026
Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.
Retension's $51.75M IPO buys a Phase 2b readout, but trial costs will set the clock
Retension's first earnings report since its upsized October IPO shows a $5.9M quarterly loss and a single catalyst: RTN-001 Phase 2b data in H1 2027. Peers show how thin other routes to capital are.
Insight Molecular's $15M raise shows how thin the small-cap diagnostics funding market is
IMDX's $1.75-per-share offering, with pre-funded warrants and a transplantation R&D pitch, sits at the small end of a financing spectrum that runs from a $51.75M IPO to royalty sales.
Kyntra's prostate exit shows how thin the funding runway is for a biotech that has to reset
After a Phase 2 interim miss, Kyntra Bio is cutting its royalty-financing cap and pivoting to roxadustat in MDS, and its plan is subject to funding in a split biotech capital market.